The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Insights into the development of the Turkish Myeloma Study Group’s 2026 treatment guidelines
In this video, Meral Beksac, MD, Istinye University Ankara Liv Hospital, Ankara, Turkey, discusses the development of the Turkish Myeloma Study Group’s 2026 treatment guidelines, which aimed to provide a comprehensive reference for national authorities and clinicians, incorporating recent data and sequencing approaches. Dr Beksac notes that the guidelines include all possibilities from the EHA-EMN and NCCN guidelines, with a focus on liberal and updated recommendations, particularly for patients with relapsed/refractory myeloma. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So in today’s practice for treatment of myeloma, we use guidelines, but we are limited with the national approvals and reimbursement limitations. And for this reason, we found a need to write, develop, and publish a national guideline. Actually, it was a request from IMS. Philippe Moreau, last year in the IMS meeting, he was announcing that they are very open to national guidelines to publish...
So in today’s practice for treatment of myeloma, we use guidelines, but we are limited with the national approvals and reimbursement limitations. And for this reason, we found a need to write, develop, and publish a national guideline. Actually, it was a request from IMS. Philippe Moreau, last year in the IMS meeting, he was announcing that they are very open to national guidelines to publish. And it took us more than a year to write and complete and publish because data in the myeloma field is very dynamic. It’s moving so fast. When you write a guideline, then new data come in. You have to revise. And this is a cat-and-mouse situation. But finally, we published it a month ago. And what we tried to do was we did not limit ourselves. We wanted to be more liberal and we wanted to include all possibilities from the EHA-EMN guideline, from the NCCN guideline. And so this could serve as a reference for the national authorities when they are giving approvals. And the EHA-EMN guidelines were published a year ago. But what we did, we added more recent data, mainly not only for newly diagnosed, but for relapsed patients, especially those bispecific and monoclonal antibody combinations. And we tried to build up a sequencing approach for patients who are triple refractory and this is I think a valuable reference which can be used for countries similar to our financial situation, middle-income country situation and also we are planning to update this frequently and there is a recent IMS approach, a guideline which is published and I think our guideline is already outdated but at least it will serve for daily practice.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
